Randy Wald
VP & Drug Product Fellow—formulation, modified-release, and scale-up expert
Summary
Work
Education
Projects
Writing
HPK1 inhibitor formulations and methods of making the same (WO2026035872A1)
February 1, 2026PCT publication disclosing formulations and unit dosage forms of HPK1 inhibitors and methods of preparing them; Randy Wald is listed as an inventor on the publication.
Oral liquid suspension of pan-raf kinase inhibitor (WO2023225029A1)
November 1, 2023PCT publication describing solid formulations for preparing oral liquid suspensions of a pan-RAF kinase inhibitor; lists Randy Wald as an inventor.
Formulations of enzalutamide (EP4169908A1 / related filings)
April 1, 2023Patent family related to amorphous solid dispersion and formulation approaches for enzalutamide; Randy J. Wald listed as an inventor on related filings.
Innovative Excipients in Solid-Dosage Manufacturing (Pharmaceutical Technology article contribution)
January 1, 2015Industry article on excipient trends and solid-dosage formulation approaches that quotes Randy Wald (then at Bend Research) on trends such as continuous processing, QbD, and specialized dosage forms.
Controlled release bead, a method of producing the same and multiple unit formulation comprising it (US6911217B1)
June 1, 2005Patent disclosing a multi-layer controlled-release bead and methods of producing it; lists Randy J. Wald among inventors.